Palisade Bio, Inc. - Common Stock PALI 深 沪
已收盘 12-12 16:00:00 美东时间
1.94
-0.260
-11.82%
华盛通- 最 高2.21
- 今 开2.20
- 成交量 455.49万股
- 最 低 1.93
- 昨 收 2.20
- 总市值 1769.12万
- 52周最高 2.59
- 市盈率 静 --
- 换手率 49.95%
- 52周最低 0.53
- 委 比 75.88%
- 总股本 911.92万
- 历史最高 18405.00
- 量 比 0.70
- 振 幅 12.73%
- 历史最低 0.53
- 每 手 1
- 风险率 0.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tilray Brands, SuperX AI Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
11-28 21:17
Palisade Bio to Present at the Piper Sandler 37th Annual Healthcare Conference
Palisade Bio, Inc. announced its CEO and Chief Medical Officer will participate in a fireside chat at Piper Sandler's 37th Annual Healthcare Conference on December 4, 2025. The event will be live streamed and replayed for accessibility. Palisade Bio is advancing a PDE4 inhibitor prodrug, PALI-2108, showing promising results in Phase 1b trials for Ulcerative Colitis and Fibrostenotic Crohn’s Disease, with plans for further Phase 2 studies. The com...
11-25 13:45
Palisade Bio Q3 EPS $(0.38) Misses $(0.27) Estimate
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.27) by 39.19 percent. This is a 83.62 percent increase over losses of $(2.32) per share from
11-11 06:50
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
Palisade Bio appoints Sharon Skare, PhD(c), as Vice President, Global Head of Clinical Operations, highlighting her 24+ years of experience in clinical development. The company is advancing PALI-2108 for ulcerative colitis and fibrostenotic Crohn’s disease, with a Phase 2 IND submission planned for H1 2026. PALI-2108 is an orally administered prodrug designed for targeted PDE4 inhibition in the终端 ileum and colon, aiming to maximize efficacy while...
10-28 12:45
Palisade Bio Doses The First Patients In Its Phase 1b Study Of PALI-2108, A First-In-Class Ileocolonic-Targeted PDE4 Inhibitor Prodrug For Fibrostenotic Crohn's Disease—A Condition With No Approved Therapies
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapiesTopline safety, PK, and PD data anticipated in Q1 2026Advances ongoing development of
10-20 20:48
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
Palisade Bio initiates Phase 1b trial of PALI-2108, a novel PDE4 inhibitor prodrug, for fibrostenotic Crohn’s disease (FSCD), a condition with no approved therapies. The study aims to evaluate safety, PK/PD, and tissue-level responses. PALI-2108 is designed for targeted activation in the terminal ileum and colon, aiming to maximize anti-inflammatory and anti-fibrotic effects while minimizing systemic exposure. Topline data expected in Q1 2026, wi...
10-20 12:45
Palisade Bio Cancels Stockholder Meeting Due to Quorum
Palisade Bio ( ($PALI) ) has provided an update. On October 9, 2025, Palisade B...
10-10 05:28
Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut
Steven Cohen's Point72 Asset Management has doubled the S&P 500's three-year return and is investing in this biotech firm...
10-08 23:30
Palisades Goldcorp任命新任首席财务官
以资源行业为核心的加拿大商业银行Palisades Goldcorp（PALI）周五宣布任命杰夫·施蒂伯（Jeff Stieber）为首席财务官，接替巴萨姆...
10-02 23:05
Palisades Goldcorp gets new finance chief
Palisades Goldcorp (TSXV:PALI:CA) appointed Jeff Stieber as the company's CFO, effective immediately. The appointment of Mr. Stieber follows the resignation of Bassam Moubarak from the post. Mr. Stieb...
10-02 16:41
